Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (12291)	11/21/1999 10:01:00 PM
From: aknahow	Respond to of 17367

But, for the "Trauma" trial the same "T" was a common factor in P II. so while a transfusion may well boost BPI levels it would have done so in the P II as well and yet, "events" were 50% less in the P III trial than in the P II trial placebo group.

To: Robert K. who wrote (12291)	11/21/1999 10:06:00 PM
From: Bluegreen	Respond to of 17367

Are you saying that Xoma is that STUPID to spend millions on a trial without proper parameters set? You aren't serious are you?

To: Robert K. who wrote (12291)	11/21/1999 11:37:00 PM
From: Robert K.	Respond to of 17367

Further reading from the public domain>"Indeed, calculations revealed that in patients receiving 2 U of packed red cells, approximately 15% of the total amount of BPI in plasma at 0.5 h after aortic unclamping can originate from the transfusion products (based on an estimated plasma volume of 4,500 mL). Alternatively, the BPI increase can be explained by either donor or recipient leukocytes becoming activated on transfusion, and at this time releasing their BPI from the azurophilic granules."